| Literature DB >> 23226757 |
Chunying Bai1, Xiaoming Yu, Rui Yun, Tiewei Shi, Chaojun Zhang, Jing Zhou, Lijuan Tong, Xiujun Li, Lifeng Gao.
Abstract
Leukotrienes are important pro-inflammatory mediators in bronchial asthma (BA) and are derived from arachidonic acid by the action of 5-lipoxygenase (5-LO). We investigated the association of 5-LO gene polymorphisms with BA. Thirty-six single-nucleotide polymorphisms (SNPs) of the 5-LO gene, as referenced in the dbSNP gene bank, were analyzed with sequencing and allele-specific PCR (AS-PCR) in genomic DNA from individuals with BA and controls. Of these 36 SNPs, 4 were identified in our study. The c.760 G>A (E254K) (rs2228065) was detected in 15 out of 215 BA patients and 6 out of 212 controls (P<0.05). There were no differences in the frequencies of the other three silent polymorphisms, rs2228064 (c.270 G>A), rs116961353 (c.780G>A) and rs2229136 (c.1728 A>G) between individuals with BA and controls (P>0.05). With our designed primers for AS-PCR, the detection of the 5-LO gene E254K polymorphism was clear and accurate, and the genotype was directly distinguished. Our findings contribute to the evaluation of one of the genetic risk factors for BA and we report an accurate and simple method to rapidly detect the 5-LO E254K polymorphism. It is important to further study the correlation between drug response in BA patients using 5-LO inhibitors with the E254K polymorphism in the clinic.Entities:
Year: 2012 PMID: 23226757 PMCID: PMC3494133 DOI: 10.3892/etm.2012.712
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Primer details for PCR to detect 4 polymorphisms by sequencing.
| Primer | Sequence | Amplified product size (bp) | Annealing temperature (°C) |
|---|---|---|---|
| c.270 G>A FP | 5′ CTC CAG AAC AAA GGC TCA GG 3′ | 360 | 56 |
| c.270 G>A RP | 5′ CCT GCA CAG CAG TGT CAT TC 3′ | ||
| c.760 G>A (E254K) FP | 5′ GCA GGG ACT CTG CTC TTA GG 3′ | 473 | 56 |
| c.760 G>A (E254K) RP | 5′ CGC AAT TCC TCC TCT GAT GT 3′ | ||
| c.780 G>A FP | 5′ GCA GGG ACT CTG CTC TTA GG 3′ | 473 | 56 |
| c.780 G>A RP | 5′ CGC AAT TCC TCC TCT GAT GT 3′ | ||
| c.1728 A>G FP | 5′ GAA AGA GGA TGG ACG GAC TG 3′ | 295 | 55 |
| c.1728 A>G RP | 5′ CTC GTT TTC CTG GAA CTG GC 3′ |
FP, forward primer; RP, reverse primer.
Figure 1Gene structure and polymorphisms investigated in the 5-LO gene. The positions marked in bold were found in polymorphisms in the Chinese Han population. 5-LO, 5-lipoxygenase.
Allele and genotype frequencies of 5-LO silent SNPs in a Chinese Han population.
| Frequency of 5-LO SNPs
| |||
|---|---|---|---|
| Allele/genotype | Non-allergic controls | Bronchial asthma patients | P-value |
| Allele | |||
| c.270 G>A | n=56 | n=65 | |
| G | 101 (0.902) | 118 (0.908) | >0.05 |
| A | 11 (0.098) | 12 (0.092) | |
| c.780 G>A | n=212 | n=215 | |
| G | 413 (0.974) | 417 (0.970) | |
| A | 11 (0.026) | 13 (0.030) | >0.05 |
| c.1728 A>G | n=56 | n=65 | |
| A | 105 (0.938) | 126 (0.969) | >0.05 |
| G | 7 (0.058) | 4 (0.033) | |
| Genotype | |||
| c.270 G>A | n=56 | n=65 | |
| GG | 45 (0.804) | 53 (0.815) | >0.05 |
| GA | 11 (0.196) | 12 (0.185) | |
| AA | 0 | 0 | |
| c.780 G>A | n=212 | n=215 | |
| GG | 201 (0.948) | 202 (0.940) | |
| GA | 11 (0.052) | 12 (0.056) | |
| AA | 0 (0) | 1 (0.005) | >0.05 |
| c.1728 A>G | n=56 | n=65 | |
| AA | 46 (0.821) | 54 (0.831) | >0.05 |
| AG | 10 (0.179) | 11 (0.169) | |
| GG | 0 | 0 | |
5-LO, 5-lipoxygenase; SNP, single-nucleotide polymorphism.
Allele and genotype frequencies of 5-LO missense SNP in a Chinese Han population.
| Frequency of 5-LO SNP
| |||
|---|---|---|---|
| Allele/genotype | Non-allergic controls (n=212) | Bronchial asthma patients (n=215) | P-value |
| c.760 G>A | |||
| Allele | |||
| G | 418 (0.986) | 415 (0.965) | |
| A | 6 (0.014) | 15 (0.035) | <0.05 |
| Genotype | |||
| GG | 206 (0.972) | 200 (0.930) | |
| GA | 6 (0.028) | 15 (0.070) | <0.05 |
| AA | 0 | 0 (0) | |
5-LO, 5-lipoxygenase; SNP, single-nucleotide polymorphism.
Figure 2Agarose gel electrophoresis results of 5-LO E254K and c.780G>A polymorphisms by AS-PCR. 1, marker I; 2 and 3, 254 wild-type GG; 4 and 5, 254 heterozygous type GA; 6 and 7, c.780 wild-type GG; 8 and 9, c.780 heterozygous type GA. 5-LO, 5-lipoxygenase; AS-PCR, allele-specific PCR.
Clinical characteristics of the controls, BA patients with E254K and BA patients without E254K.
| Clinical characteristics | Normal range | Controls (n=50) mean ± SD | BA with E254K (n=14) mean ± SD | BA without E254K (n=114) mean ± SD | P-value (t-test)
| ||
|---|---|---|---|---|---|---|---|
| P1 | P2 | P3 | |||||
| WBC (109/l) | 4–10 | 8.07±1.6 | 7.86±3.49 | 8.79±3.7 | 0.852 | 0.445 | 0.496 |
| LYMPH% | 20–40 | 30.94±15.72 | 61.72±15.71 | 54.81±18.72 | 0.314 | ||
| MONO% | 3–8 | 5.62±1.6 | 8.88±1.81 | 9.2±3.54 | 0.807 | ||
| NEUT% | 50–75 | 60.34±8.56 | 28.15±16.25 | 33.97±19.72 | 0.42 | ||
| EO% | 1–3 | 1.78±0.55 | 1.07±0.98 | 2.09±3.16 | 0.698 | 0.369 | |
| BASO% | 0–1 | 0.25±0.16 | 0.26±0.2 | 0.31±0.3 | 0.888 | 0.450 | 0.666 |
| LYMPH# (109/1) | 0.8–4 | 3.38±1.26 | 4.95±2.89 | 4.85±3.03 | 0.091 | 0.059 | 0.931 |
| MONO# (109/1) | 0.12–1.8 | 0.61±0.38 | 0.66±0.38 | 0.80±0.44 | 0.742 | 0.094 | 0.365 |
| NEUT# (109/1) | 2–7.5 | 4.86±2.35 | 2.16±1.35 | 2.92±2.14 | 0.325 | ||
| EO# (109/1) | 0–0.45 | 0.11±0.10 | 0.08±0.07 | 0.18±0.27 | 0.426 | 0.351 | 0.310 |
| PLT (109/l) | 100–300 | 238.63±65.08 | 333.38±129.46 | 320.35±106.32 | 0.744 | ||
P1, P-value comparing individuals with BA with E254K and controls; P2, P-value comparing individuals with BA without E254K and controls; P3, P-value comparing individuals with BA with E254K and BA without E254K. WBC, white blood cell; LYMPH, lymphocytes; MONO, monocytes; NEUT, neutrophils; EO, eosinophils; PLT, platelets; BA, bronchial asthma. The percentages of lymphocytes, monocytes and platelets levels were significantly higher in individuals with BA (without or with E254K) than in controls (P<0.05). By contrast, the percentage and number of neutrophils were significantly lower than in controls (P<0.05). P<0.05 in bold.